Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
ACS, addressing, aggressive, APEL, AssistTM, AstraZeneca, Austria, barrier, Bermuda, book, Caribbean, Centerview, Chapter, Chile, CMS, Colombia, consummation, contest, cooperate, cooperation, Czech, deconsolidated, deconsolidation, deficiency, Denmark, derecognition, derecognized, DIFICLIRTM, distract, DOJ, ENTEREG, FCPA, fill, filling, Finland, forfeited, formal, France, Germany, HCST, hematopoietic, HSCT, Hungary, Iceland, improper, instigated, intangible, interview, intraperiod, issuable, ITT, Justice, lab, lawsuit, leadership, licensee, Luxembourg, Meredith, Morgan, multicenter, newman, Norway, Notwithstanding, NTAP, Omnicare, Portugal, preliminary, premium, prepaid, Pty, readjusted, recoded, remedial, remediate, remediated, Republic, role, routine, Rx, salary, Schaum, Slovenia, source, Spain, Specialised, STA, stem, step, stephen, succeeded, Sweden, tangible, Taxpayer, tender, threshold, UK, unallocated, uncontrolled, undertaken, unsuccessfully, vast, waived, webster, withholding
Removed:
adjuvant, adult, advancing, Allergy, allocable, analyzed, antigen, array, Asia, assay, belonged, BI, blood, building, built, carrier, chemistry, Chemotherapy, cited, compare, composed, Composite, confirm, confirmed, controlling, credited, cumulatively, cured, De, desirable, diagnosed, discovering, discretionary, dominant, dosed, economically, England, Enterococci, epidemic, evaluable, excessive, exclusively, expend, expired, explicit, exploratory, feasibility, Finally, fluctuation, Globo, glycooptimization, Glycosylation, grow, half, hypervirulent, ICAAC, input, integrity, Interscience, journal, lung, marketplace, median, Medicine, metabolite, metastasized, microbiologically, mild, modification, MSKCC, narrow, National, NIAID, NIH, nonexclusive, nonrefundable, Novo, onset, participated, patented, placement, platform, potency, predominantly, premarketing, projected, prominent, promising, prone, prosecute, prostate, protein, protocol, randomly, rapid, recommend, recourse, regained, release, relinquish, resist, safely, sample, scheduled, sialyl, simple, Society, steep, stimulate, stool, subjective, sublicensee, sublicensing, subset, suggested, superiority, supplement, survey, survived, synthetic, toxicology, transferable, tumor, ultimately, unfavorable, unformed, unproven, upfront, visit, week, white, women
Filing tables
Filing exhibits
Related press release
OPTR similar filings
Filing view
External links